New Generics for Solodyn Launched
February 20, 2018 – Teva Pharmaceuticals has launched its generics for Solodyn® (minocycline) extended-release 65mg and 115mg tablets. Solodyn is manufactured by Medicis. Both brand and generics are indicated for treatment of moderate to severe acne in patients who are at least twelve years of age.
Although Teva is to have 180 days of exclusivity, Impax, a subsidiary of Valeant Pharmaceuticals, has announced the launch of its own authorized generic version of Solodyn 65mg and 115mg tablets.
According to IQVIA, total annual sales for Solodyn 65mg and 115mg extended release tablets reached $148 million in the U.S. in 2017.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.